News Article | May 15, 2017
-- Cavignac & Associates, a downtown San Diego-based risk management and insurance brokerage firm, has hired Nicole Laforteza as an account administrator within the agency's Employee Benefits Department, announced Jeffrey W. Cavignac, CPCU, RPLU, CRIS, company principal and founder.Laforteza's primary responsibility is to assist the department's account manager with daily service activities for each client's benefit offerings. Specifically, she coordinates requests for proposals and prepares quotations for new and renewal coverage; compiles open enrollment materials; creates spreadsheets, presentations and proposals for new and renewal business; and prepares packages of material for open enrollment meetings, sometimes handling those meetings if requested.Prior to joining Cavignac & Associates, Laforteza served as a bookkeeper and administrative assistant for Dunne & Dunne, LLP, where she worked for five-and-a-half years. There she maintained all client accounts, prepared client invoices, collected replenishments and assisted all of the firm's associate attorneys.A graduate of California State University, Long Beach, Laforteza holds a Bachelor of Arts degree in journalism, with an emphasis in public relations and minor in communication studies. Currently she is a graduate student at National University, where she is working toward her graduate degree in strategic communication.Born in the Philippines and raised in San Diego, Laforteza currently resides in the San Diego community of Chula Vista. She enjoys various sports, especially basketball, running and hiking. Her other leisure time activities include playing with her three dogs, photography, and going on spontaneous adventures to Orange County, Los Angeles, and hidden spots within San Diego.Founded in 1992, Cavignac & Associates is a leading risk management and commercial insurance brokerage firm providing a broad range of insurance and expertise to design and construction firms, as well as to law firms, real estate-related entities, manufacturing companies and the general business community. Company principals are Jeffrey W. Cavignac, CPCU, ARM, RPLU, CRIS, MLIS; James P. Schabarum II, CPCU, AFSB; Scott A. Bedingfield, AAI, CIC, CRIS; Patrick Casinelli, RHU, REBC, CHRS; Matthew Slakoff, CIC, CRIS; and Matthew Noonan, RHU, CIC, CHRS, CCWS. The firm employs a staff of more than 50 at offices located at 450 B Street, Suite 1800, San Diego, Calif., 92101. More information about the company can be found at www.cavignac.com
News Article | December 2, 2016
Nearly one in 11 Americans will have a kidney stone in their lifetime, causing pain, sometimes missed work and, often, a lot of money. And for the two-thirds of kidney stone patients who need more than just extra hydration to pass their stones, physicians are eager to find non-surgical ways to help. Contemporary practice guidelines recommend off-label use of drugs called alpha blockers to facilitate stone passage. These include drugs such as such as tamsulosin, known as Flomax. However, a recent multicenter study of 1,136 subjects in the U.K. questioned the effectiveness of alpha blockers for this purpose. Now, a new review of the medical literature suggests alpha blockers may be useful in some cases. It's published online December 1 in The BMJ (link is external), formerly known as the British Medical Journal. "If we can facilitate kidney stone passage without surgery, it allows our patients to avoid extra pain and risks that come with a surgical procedure," says first author John M. Hollingsworth, M.D., associate professor of urology at the University of Michigan Medical School. "When the 2015 study (link is external) did not show a significant difference between alpha blockers and placebos, we wanted to explore the issue further." Hollingsworth and his team put that 2015 study into the context of other kidney stone research, pooling a total of 55 randomized controlled trials comparing alpha blockers to placebo or control. They then considered stone size and location in the 5,990 study subjects to see if either one was a factor in successfully passing the stone. "We found alpha blockers were successful, but the benefit is primarily in patients with larger kidney stones," says co-author Benjamin K. Canales, M.D., associate professor of urology at the University of Florida College of Medicine. Researchers report a 57 percent higher risk of stone passage for larger stones with an alpha blocker, but no benefit for smaller stones. Location did not make a difference, nor did type of alpha blocker used. "It's important not to discount low-risk options for patients who may benefit from them," says senior author Philipp Dahm, M.D., professor of urology at the University of Minnesota Medical School. "Our findings suggest providers consider prescribing a course of an alpha blocker." "This data helps me better identify the patients who are likely to benefit from alpha blockers," Hollingsworth says. "It's important to consider stone size when deciding whether to recommend alpha blockers to kidney stone patients." Because so many providers see kidney stones, from urologists like Hollingsworth to emergency department physicians and primary care physicians, the treatment guidelines are especially important, he says. "There had been a fair amount of ambiguity following the UK trial. However, our findings help solidify surrounding guideline recommendations on alpha blockers in patients with stones," Hollingsworth says. Additional authors: In addition to Hollingsworth, Canales and Dahm, authors include U-M's Mary A. M. Rogers, Ph.D., M.S. and Phyllis Yan, the University of Minnesota's Shyam Sukumar, M.D., and the University of Florida's Gretchen M. Kuntz, MSW, MLIS. Hollingsworth and Rogers are members of the U-M Institute for Healthcare Policy and Innovation. Disclosure: Hollingsworth has research grants from the Agency for Healthcare Research and Quality, the Urology Care Foundation, and Blue Cross Blue Shield of Michigan. Reference: "Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis," The BMJ, online Dec. 1, 2016.
Zahedi Z.,Persian Gulf University |
Shirazi M.S.,MLIS |
Dehghani L.,Bushehr University of Medical Sciences
Information Sciences and Technology | Year: 2010
The World Wide Web is an important information sour for scholarly communications. Examining the inlinks via webometrics studies has attracted particular interests among information researchers. In this study, the number of inlinks to 69 ISI medical journals retrieved by Yahoo, AltaVista, and All The web Engines were examined via a comparative and Webometric s study. For data analysis, SPSS software was employed. Findings revealed that British Medical Journal website attracted the most links of all in the three search engines. There is a significant number of External links and the ISI impact factor. The most significant correlation in the three search engines exists between external links of Yahoo and AltaVista (100%) and the least correlation is found between external links o of AltaVista (0.51). There is no significant difference between the internal links & the number of pages found by the three search engines. But in case of impact factors, significant differences are found between these three search engines. So, the study shows that journals with higher impact factor attract more links to their websites. It also indicates that the three search engines are significantly different in terms of total links, outlinks and web impact factors.
Gazni A.,Islamic World Science Citation Center |
Gazni A.,Shahid Chamran University |
Scientometrics | Year: 2011
This study aims to investigate the influence of different patterns of collaboration on the citation impact of Harvard University's publications. Those documents published by researchers affiliated with Harvard University in WoS from 2000-2009, constituted the population of the research which was counted for 124,937 records. Based on the results, only 12% of Harvard publications were single author publications. Different patterns of collaboration were investigated in different subject fields. In all 22 examined fields, the number of co-authored publications is much higher than single author publications. In fact, more than 60% of all publications in each field are multi-author publications. Also, the normalized citation per paper for co-authored publications is higher than that of single author publications in all fields. In addition, the largest number of publications in all 22 fields were also published through inter-institutional collaboration and were as a result of collaboration among domestic researchers and not international ones. In general, the results of the study showed that there was a significant positive correlation between the number of authors and the number of citations in Harvard publications. In addition, publications with more number of institutions have received more number of citations, whereas publications with more number of foreign collaborators were not much highly cited. © 2011 Akadémiai Kiadó, Budapest, Hungary.
News Article | February 15, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "UK Medico-Legal and Insurance Services Market - Legal Market Briefing" report to their offering. The 'UK Medico-Legal and Insurance Market Briefing' is the first edition of an annual Legal Market Briefing and provides an overview of the market for medico-legal and insurance services (MLIS), including profiles of companies operating in the market. This market offers two main types of services to legal services providers, insurers and employers: Medical expertise (ME), i.e. medical expert witnesses and medico-legal report writing; and Rehabilitation and allied medical services (RAMS), i.e. medical services to rehabilitate and help an injured or ill individual. The range of players in the MLIS market is large, ranging from thousands of individual medical practitioners up to companies which are part of national and international claims management, claims processing and legal services companies. While some companies in the market operate across both segments, others specialize fully or mainly in just one segment. The companies operating in the market include those that are fully independent, those owned by insurance companies, those owned by legal services companies and captives (of insurers or legal firms). The market for MLIS services, based on the turnover of the companies operating, was estimated to be worth over £600 million in 2016, having grown from over £500 million in 2013. Growth in the market has slowed recently. Strong positive drivers of growth have been: - The growing focus on rehabilitation and psychological rehab by the insurance and legal professions, - The growing volume of work for expert witnesses in 2015/16, - The growing use of RAMs services for lower-value claims. - The growing restrictions that have (and are due to) come into force in the personal injury market, either reducing the number of claims or cutting their costs, - The fact that expert witnesses report that it is a harder market to operate in because of legal changes and rulings, For more information about this report visit http://www.researchandmarkets.com/research/5gjgcw/uk_medicolegals.